Loading clinical trials...
Loading clinical trials...
A 6-week, Double-blind, Placebo-controlled, Randomized, Multicenter Study to Explore the Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With OFF Time and Moderate-severe L-dopa Induced Dyskinesia
This Phase IIb exploratory study is designed to determine whether AFQ056 is safe and effective and whether it can increase the therapeutic window of L-dopa in patients whose control of their Parkinson's Disease symptoms is limited by the development of dyskinesia induced by use of L-dopa.
Age
30 - 80 years
Sex
ALL
Healthy Volunteers
No
The Parkinsons Institute
Sunnyvale, California, United States
Colorado Neurological Institute
Englewood, Colorado, United States
Indiana University School of Medicine
Indianapolis, Indiana, United States
University of Kansas Medical Center - Parkinson's Disease and Movement Disorders Center
Kansas City, Kansas, United States
Start Date
March 1, 2010
Primary Completion Date
July 1, 2011
Completion Date
July 1, 2011
Last Updated
December 23, 2020
23
ACTUAL participants
AFQ056 with L-dopa
DRUG
Placebo
DRUG
Lead Sponsor
Novartis
NCT07310264
NCT02119611
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07216976